Current Gaps in Therapy in Patients with Nontuberculous Mycobacterial Lung Disease (NTM-LD): Improving Adherence With Guideline-Recommended Strategies
Monday, May 22, 2023
6:45 PM – 7:45 PM EST
5:45 PM – 6:45 PM CST
4:45 PM – 5:45 PM MST
3:45 PM – 4:45 PM PST
Features:
- Interactive case-based presentation
- Downloadable whiteboard animations
- Create-your-own personalized poster portal
An evening symposia educational program sponsored by Med Learning Group and supported by a grant from Insmed open to all ATS 2023 International Conference attendees.
Learning Objectives
After completing the CME activity, learners should be better able to:
- Assess best practices in reducing time to diagnosis of NTM-LD in patients with nonspecific symptoms
- Explain best practices for treatment selection in NTM-LD, both in the frontline and refractory setting, as informed by clinical guidelines
- Interpret data from clinical trials concerning the role of amikacin liposome inhalation suspension (ALIS) in the treatment of patients with NTM-LD
- Summarize strategies for avoidance of adverse events associated with NTM-LD therapies and strategies for improving patient and clinician communication to optimize therapeutic persistence
Target Audience
This activity is designed to meet the educational needs of pulmonology professionals (including MDs, DOs, NPs, PAs and pharmacists) who have a role in the diagnosis and treatment of patients with NTM-LD.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure Of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Disclaimer
Med Learning Group makes every effort to develop activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For questions, please contact Med Learning Group at info@medlearninggroup.com.
Contact this provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Release date: May 22, 2023
Expiration date: May 22, 2024
Estimated time to completion: 1.0 hour
